HRP20191655T1 - N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt - Google Patents

N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt Download PDF

Info

Publication number
HRP20191655T1
HRP20191655T1 HRP20191655T HRP20191655T1 HR P20191655 T1 HRP20191655 T1 HR P20191655T1 HR P20191655 T HRP20191655 T HR P20191655T HR P20191655 T1 HRP20191655 T1 HR P20191655T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
composition according
compound
treatment
migraine headaches
Prior art date
Application number
Other languages
Croatian (hr)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20191655(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HRP20191655T1 publication Critical patent/HRP20191655T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (13)

1. Čvrsta farmaceutska kompozicija u doznom jediničnom obliku, koja sadrži, po dozi, od 1 mg do 1000 mg hemisulfat soli spoja (I): i farmaceutski prihvatljiv nosač ili razblaživač.1. A solid pharmaceutical composition in dosage unit form, which contains, per dose, from 1 mg to 1000 mg of the hemisulfate salt of compound (I): and a pharmaceutically acceptable carrier or diluent. 2. Farmaceutska kompozicija u formi oralnog doznog oblika, koji sadrži od 70 mg do 750 mg hemisulfat soli spoja (I) u skladu sa patentnim zahtjevom 1.2. Pharmaceutical composition in the form of an oral dosage form, which contains from 70 mg to 750 mg of the hemisulfate salt of compound (I) in accordance with patent claim 1. 3. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 2, koja sadrži 70 mg hemisulfat soli spoja (I).3. Pharmaceutical composition according to claim 2, which contains 70 mg of the hemisulfate salt of compound (I). 4. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 2, koja sadrži 80 mg hemisulfat soli spoja (I).4. Pharmaceutical composition according to claim 2, which contains 80 mg of the hemisulfate salt of compound (I). 5. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 4 gdje hemisulfat sol spoja (I) je seskvihidrat.5. A pharmaceutical composition according to any one of claims 1 to 4, wherein the hemisulfate salt of compound (I) is a sesquihydrate. 6. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 5 gdje hemisulfat sol spoja (I) je kristalni oblik H1.5-1 koji je naznačen sljedećim: parametri jedinične stanice suštinski jednaki sljedećim: Prostorna grupa: P21212 Molekule spoja (I)/asimetrična jedinica: 1 Zapremina = 2851 Å3 Gustoća (izračunato) = 1.423 g/cm3, pri čemu je mjerenje navedenog kristalnog oblika na temperaturi od oko 25°C.6. Pharmaceutical composition according to any one of claims 1 to 5, where the hemisulfate salt of the compound (I) is the crystalline form H1.5-1 which is indicated as follows: unit cell parameters essentially equal to the following: Spatial group: P21212 Molecules of compound (I)/asymmetric unit: 1 Volume = 2851 Å3 Density (calculated) = 1.423 g/cm3, whereby the measurement of the specified crystalline form is at a temperature of about 25°C. 7. Farmaceutska kompozicija u skladu sa patentnim zahtjevom 6 gdje je navedeni oblik H1.5-1 naznačen sa jednim ili više od sljedećeg: a) shema rendgenske difrakcije na prahu (CuKα λ=1.5418Å) koji sadrži sljedeće 2θ vrijednosti: 5.4±0.1, 8.6±0.1, 9.7±0.1, 12.4±0.1, 14.9±0.1,17.6±0.1, 18.1±0.1, 20.5±0.1, 21.4±0.1, i 22.0±0.1, pri čemu je mjerenje kristalnog oblika na temperaturi od oko 25°C; i/ili b) spektri nuklearne rezonance u čvrstom stanju koji sadrže sljedeće pikove (δ (ppm) navedeni kao TMS): 26.6±0.1, 27.1±0.1, 28.3±0.1, 30.7±0.1, 43.1±0.1, 45.9±0.1, 47.1±0.1, 52.0±0.1, 54.2±0.1, 72.5±0.1, 117.0±0.1, 117.7±0.1, 124.2±0.1, 125.2±0.1, 128.3±0.1, 130.3±0.1, 131.4±0.1, 134.1±0.1, 140.8±0.1, 144.7±0.1, 148.7±0.1, 149.8±0.1, 151.2±0.1, 153.4±0.1, 155.1±0.1, 155.6±0.1, i 156.7±0.1.7. Pharmaceutical composition according to patent claim 6, where said form H1.5-1 is indicated with one or more of the following: a) X-ray diffraction pattern on powder (CuKα λ=1.5418Å) containing the following 2θ values: 5.4±0.1, 8.6±0.1, 9.7±0.1, 12.4±0.1, 14.9±0.1, 17.6±0.1, 18.1±0.1, 20.5± 0.1, 21.4±0.1, and 22.0±0.1, whereby the measurement of the crystalline form is at a temperature of about 25°C; and/or b) solid state nuclear resonance spectra containing the following peaks (δ (ppm) reported as TMS): 26.6±0.1, 27.1±0.1, 28.3±0.1, 30.7±0.1, 43.1±0.1, 45.9±0.1, 47.1±0.1, 52.0±0.1, 54.2±0.1, 72.5±0.1, 117.0±0.1, 117.7±0.1, 124.2±0.1, 125.2±0.1, 128.3±0.1, 130.3±0.1, 131.4±0.1, 134.1±0.1, 140.17, 140.8±4. 0.1, 148.7±0.1, 149.8±0.1, 151.2±0.1, 153.4±0.1, 155.1±0.1, 155.6±0.1, and 156.7±0.1. 8. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za primjenu u liječenju migrenskih glavobolja.8. Pharmaceutical composition according to any one of claims 1 to 7 for use in the treatment of migraine headaches. 9. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za oralno administriranje koje je korisno za liječenje migrenskih glavobolja.9. A pharmaceutical composition according to any one of claims 1 to 7 for oral administration which is useful for the treatment of migraine headaches. 10. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za sublingvalno administriranje koje je korisno za liječenje migrenskih glavobolja.10. A pharmaceutical composition according to any one of claims 1 to 7 for sublingual administration which is useful for the treatment of migraine headaches. 11. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za intranazalno administriranje koje je korisno za liječenje migrenskih glavobolja.11. A pharmaceutical composition according to any one of claims 1 to 7 for intranasal administration which is useful for the treatment of migraine headaches. 12. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za primjenu jednom dnevno u liječenju migrenskih glavobolja.12. A pharmaceutical composition according to any one of claims 1 to 7 for use once a day in the treatment of migraine headaches. 13. Farmaceutska kompozicija u skladu sa bilo kojim od patentnih zahtjeva 1 do 7 za primjenu dva puta dnevno u liječenju migrenskih glavobolja.13. A pharmaceutical composition according to any one of claims 1 to 7 for use twice a day in the treatment of migraine headaches.
HRP20191655 2012-02-27 2019-09-16 N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt HRP20191655T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27
EP17180587.2A EP3254681B1 (en) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt

Publications (1)

Publication Number Publication Date
HRP20191655T1 true HRP20191655T1 (en) 2019-12-13

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20171620TT HRP20171620T1 (en) 2012-02-27 2017-10-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt
HRP20191655 HRP20191655T1 (en) 2012-02-27 2019-09-16 N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20171620TT HRP20171620T1 (en) 2012-02-27 2017-10-25 N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b]pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b]pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt

Country Status (25)

Country Link
US (1) US8759372B2 (en)
EP (2) EP2820016B1 (en)
JP (2) JP6208154B2 (en)
KR (2) KR102220969B1 (en)
CN (1) CN104136437B (en)
AU (1) AU2013226361B2 (en)
BR (1) BR112014021032B1 (en)
CA (1) CA2865585C (en)
CY (2) CY1119448T1 (en)
DK (2) DK3254681T3 (en)
EA (1) EA025358B1 (en)
ES (2) ES2746031T3 (en)
HK (1) HK1248111B (en)
HR (2) HRP20171620T1 (en)
HU (2) HUE034936T2 (en)
IL (1) IL234272B (en)
LT (2) LT2820016T (en)
MX (1) MX352171B (en)
NO (1) NO2935439T3 (en)
PL (2) PL3254681T3 (en)
PT (2) PT3254681T (en)
RS (2) RS59295B1 (en)
SG (1) SG11201404834XA (en)
SI (2) SI3254681T1 (en)
WO (1) WO2013130402A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
BR112014021032B1 (en) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUORO-PHENYL)-6,7,8,9-TETRAHYDRO-5H-ICLOHEPTA[B]PYRIDIN-9 HEMISULFATE SALT -IL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-IL}-PIPERIDINE-1-CARBOXYLATE, ITS USE AND PHARMACEUTICAL COMPOSITION INCLUDING IT
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US9828410B2 (en) 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
ES2965087T3 (en) * 2016-09-02 2024-04-10 Soares Christopher J Use of CGRP receptor antagonists in the treatment of glaucoma
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
JP7066728B2 (en) * 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Nucleotide hemi sulfate for the treatment of hepatitis C virus
JP2021519288A (en) * 2018-03-25 2021-08-10 バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． Limegepant for CGRP-related disorders
JP2021521118A (en) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド Treatment of HCV-infected patients with cirrhosis
KR20210116560A (en) * 2019-01-20 2021-09-27 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. CGRP antagonists to treat migraine outbreaks
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2024509165A (en) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー Treating and/or reducing the occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023034466A1 (en) * 2021-09-02 2023-03-09 Pfizer Ireland Pharmaceuticals Cgrp antagonists for treating psoriasis
CN115850266A (en) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 Novel crystal form of rimazepam and preparation method thereof
CN116554164A (en) * 2022-01-27 2023-08-08 奥锐特药业(天津)有限公司 Preparation method of zimetapam
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (en) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd CARBOXYLIC ACID SALT DERIVATIVE FROM NAPHTHYRIDINE.
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن CGRP receptor antagonists
EP1726590A4 (en) 2004-03-05 2009-07-15 Banyu Pharma Co Ltd Cycloalkanopyridine derivative
KR20070062997A (en) 2004-10-13 2007-06-18 머크 앤드 캄파니 인코포레이티드 Cgrp receptor antagonists
EP1804919B1 (en) 2004-10-22 2011-03-30 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
WO2007120590A2 (en) 2006-04-10 2007-10-25 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (en) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline compounds
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
BR112014021032B1 (en) * 2012-02-27 2022-09-27 Bristol-Myers Squibb Company N-(5S,6S,9R)-5-AMINO-6-(2,3-DIFLUORO-PHENYL)-6,7,8,9-TETRAHYDRO-5H-ICLOHEPTA[B]PYRIDIN-9 HEMISULFATE SALT -IL-4-(2-OXO-2,3-DIHYDRO-1H-IMIDAZO[4,5-B]PYRIDIN-1-IL}-PIPERIDINE-1-CARBOXYLATE, ITS USE AND PHARMACEUTICAL COMPOSITION INCLUDING IT

Also Published As

Publication number Publication date
JP2017226693A (en) 2017-12-28
CN104136437B (en) 2016-05-11
KR20140130140A (en) 2014-11-07
RS59295B1 (en) 2019-10-31
JP6208154B2 (en) 2017-10-04
JP2015511581A (en) 2015-04-20
MX352171B (en) 2017-11-13
EA201491585A1 (en) 2015-01-30
CY1119448T1 (en) 2018-03-07
PT2820016T (en) 2017-10-18
EP2820016B1 (en) 2017-08-02
SI2820016T1 (en) 2017-11-30
SI3254681T1 (en) 2019-10-30
KR102220969B1 (en) 2021-02-25
CA2865585A1 (en) 2013-09-06
ES2642737T3 (en) 2017-11-17
MX2014009544A (en) 2014-11-10
PL2820016T3 (en) 2018-01-31
CA2865585C (en) 2019-12-10
CN104136437A (en) 2014-11-05
RS56556B1 (en) 2018-02-28
SG11201404834XA (en) 2014-09-26
DK3254681T3 (en) 2019-09-30
HUE047050T2 (en) 2020-04-28
HRP20171620T1 (en) 2017-12-01
CY1122121T1 (en) 2020-11-25
US8759372B2 (en) 2014-06-24
LT3254681T (en) 2019-09-25
EP2820016A1 (en) 2015-01-07
ES2746031T3 (en) 2020-03-04
BR112014021032B1 (en) 2022-09-27
KR102076118B1 (en) 2020-02-11
KR20200016993A (en) 2020-02-17
EA025358B1 (en) 2016-12-30
US20130225636A1 (en) 2013-08-29
IL234272B (en) 2018-10-31
WO2013130402A1 (en) 2013-09-06
HUE034936T2 (en) 2018-03-28
NO2935439T3 (en) 2018-03-31
LT2820016T (en) 2017-10-25
PT3254681T (en) 2019-10-01
AU2013226361A1 (en) 2014-10-16
JP6476253B2 (en) 2019-02-27
EP3254681B1 (en) 2019-06-19
HK1248111B (en) 2020-04-17
PL3254681T3 (en) 2019-12-31
AU2013226361B2 (en) 2017-09-21
DK2820016T3 (en) 2017-11-13
EP3254681A1 (en) 2017-12-13
BR112014021032A2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
HRP20191655T1 (en) N-(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate salt
HK1149258A1 (en) Compounds
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
MY150519A (en) Imidazoquinolines with immuno-modulating properties
UA108926C2 (en) LibreOfficeKINASE PYRROLO[2,3-DEPENDENT INHIBITORS
MX354102B (en) Benzimidazole-proline derivatives.
AR090151A1 (en) RAF INHIBITING COMPOUNDS
AR067757A1 (en) IMIDAZO DERIVATIVES [4,5-C] PIRIDIN-2-ONA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE PREPARATION AND USE OF THE SAME AS ANTIVIRAL AGENTS.
HRP20150356T1 (en) Crystalline forms of prasugrel salts
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
PH12015500063A1 (en) Azaindole derivatives which act as pi3k inhibitors
SG195106A1 (en) Trpv4 antagonists
WO2014152996A8 (en) Crystalline form of a beta-lactamase inhibitor
HRP20171824T1 (en) (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
EP2786998A4 (en) Thienyl [3, 2-d]pyrimidin-4-one compounds, preparation method, pharmaceutical compositions and use thereof
RS53900B1 (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2012062905A3 (en) Chromene derivatives and their analoga as wnt pathway antagonists
HRP20210158T1 (en) Method and system for displacing a fluid from a supply container to a delivery component
WO2014053968A8 (en) Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
EP2549874A4 (en) Substituted imidazo[1,2-b]pyridazine derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors
TN2016000061A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
HRP20180386T1 (en) Pharmaceutically active compounds
NZ607658A (en) Heterocyclyl compounds as Histamine H3 receptor ligands
MY165623A (en) 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2013024358A3 (en) Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors